Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-02 21:05:01 - browse：827

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Latigo launches with $135 million for Vertex

knowledge

WSS

Doctors on social media are being harassed and cyberbullied

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Having children helps parents live longer, especially after age 80

Resistance to opioid

Christmas in the PICU brings some surprising joy

Artificial intelligence use in health care faces greater scrutiny in 2024

hotspot

Wikipedia

explore

Bright Health sells Medicare Advantage business to Molina

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Medicare proposal to cover medical devices draws a mixed reaction

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

ChatGPT in medicine: STAT answers readers' burning questions

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

23andMe had bad news about my health. I wish a person had delivered it

Congress might make insulin pumps more accessible to the blind

Sports medicine is finally prioritizing gender equality

Grail spinoff by Illumina should end disastrous merger attempt

Wikipedia

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Three trends to watch in biotech in 2024

Why health care costs have stayed mostly flat since 2010

Why Eli Lilly’s earnings didn’t quite live up to the hype

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

explore

hotspot

knowledge

leisure time